NICE issues Appraisal Consultation Document on ruxolitinib (Jakavi) for treatment of splenomegaly and symptoms linked to myelofibrosis

Source: NICE Area: News NICE has issued new draft guidance not recommending ruxolitinib (Jakavi), for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adults with primary myelofibrosis, or myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia.   The Committee noted that ruxolitinib was effective in reducing spleen size and in treating symptoms, such as itch and fatigue; and although it was plausible that ruxolitinib could offer a survival benefit, there were uncertainties in the data used by the manufacturer to estimate the degree of survival benefit. The Evidence Review Group had concerns around the limitations of the manufacturer's economic model and many of the modelling assumptions; and considered that, on balance, the ICER was likely to be closer to £149,000 per quality-adjusted life year (QALY) gained, rather than £74,000 per QALY gained, as presented by the manufacturer. Therefore the Committee concluded that ruxolitinib was clinically ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news